Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project

Rafael Marcos-Gragera,1 Claudia Allemani,2 Carmen Tereanu,2 Roberta De Angelis,7 Riccardo Capocaccia,5 Marc Maynadie,7 Stefano Luminari,5 Stefano Ferretti,6 Tom Børge Johannesen,7 Risto Sankila,8 Marja-Liisa Karjalainen-Lindsberg,7 Arianna Simonetti,3 Maria Carmen Martos,10,11 Martine Raphaël,12 Pilar Giraldo,11,13 the HAEMACARE Working Group, and Milena Sant2,14

1Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health and Catalan Institute of Oncology, Girona, Spain; 2Analytical Epidemiology Unit, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 3National Centre for Epidemiology, Surveillance and Health Promotion, Department of Cancer Epidemiology, Istituto Superiore di Sanità, Rome, Italy; 4Côte d’Or Haematological Malignancies Registry, EA 4184, University of Burgundy, Dijon, France; 5Department of Oncology and Haematology and Modena Cancer Registry, University of Modena and Reggio Emilia, Modena, Italy; 6Ferrara Cancer Registry, Pathology Section, Department of Experimental and Diagnostic Medicine, Ferrara University, Italy; 7Department of Clinical and Registry-Based Research, The Norwegian Cancer Registry; 8Finnish Cancer Registry, Helsinki, Finland; 9Department of Pathology, Helsinki University Central Hospital, Helsinki, Finland; 10Center for Public Health Research, Valencia, Spain; 11Cancer Registry of Zaragoza, Aragon Institute of Health Sciences, Zaragoza, Spain; 12Department of Haematology, Le Kremlin-Bicêtre, University Paris-Sud, France; 13Department of Haematology, Hospital Universitario Miguel Servet, Zaragoza, Spain; 14HAEMACARE Project Leader

ABSTRACT

Background
The European Cancer Registry-based project on hematologic malignancies (HAEMACARE), set up to improve the availability and standardization of data on hematologic malignancies in Europe, used the European Cancer Registry-based project on survival and care of cancer patients (EUROCARE-4) database to produce a new grouping of hematologic neoplasms (defined by the International Classification of Diseases for Oncology, Third Edition and the 2001/2008 World Health Organization classifications) for epidemiological and public health purposes. We analyzed survival for lymphoid neoplasms in Europe by disease group, comparing survival between different European regions by age and sex.

Design and Methods
Incident neoplasms recorded between 1995 to 2002 in 48 population-based cancer registries in 20 countries participating in EUROCare-4 were analyzed. The period approach was used to estimate 5-year relative survival rates for patients diagnosed in 2000-2002, who did not have 5 years of follow up.

Results
The 5-year relative survival rate was 57% overall but varied markedly between the defined groups. Variation in survival within the groups was relatively limited across European regions and less than in previous years. Survival differences between men and women were small. The relative survival for patients with all lymphoid neoplasms decreased substantially after the age of 50. The proportion of ‘not otherwise specified’ diagnoses increased with advancing age.

Conclusions
This is the first study to analyze survival of patients with lymphoid neoplasms, divided into groups characterized by similar epidemiological and clinical characteristics, providing a benchmark for more detailed analyses. This Europe-wide study suggests that previously noted differences in survival between regions have tended to decrease. The survival of patients with all neoplasms decreased markedly with age, while the proportion of ‘not otherwise specified’ diagnoses increased with advancing age. Thus the quality of diagnostic work-up and care decreased with age, suggesting that older patients may not be receiving optimal treatment.

Key words: lymphoid malignancies, survival, outcome.


©2011 Ferrata Storti Foundation. This is an open-access paper.
Introduction

Lymphoid neoplasms are a heterogeneous group of hematologic malignancies that include non-Hodgkin’s lymphoma (NHL), Hodgkin’s lymphoma (HL), plasma cell neoplasms and lymphoid leukemias. Various classifications of these diseases, based mainly on morphological and clinical criteria, were used in the past, but these were superseded by the Revised European-American Lymphoma (REAL) classification of 1994 which included immunophenotypic and genotypic, as well as morphological and clinical, criteria. The World Health Organization (WHO) introduced a new classification in 2001. This was based on the REAL classification but gained broader consensus and, together with the revised WHO classification of 2008, is now widely used by clinicians and pathologists. The WHO terminology was incorporated into the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) which uses all available criteria to distinguish the various entities of lymphoid neoplasms according to cell lineage and level of differentiation.

Since the ICD-O-3 has been adopted by most European population-based cancer registries it has now become possible, for the first time, to analyze the survival of patients with lymphoid neoplasms in Europe using an internationally recognized disease classification system. Nevertheless major difficulties remain: it is not possible to analyze each disease entity (defined by ICD-O-3 code) separately; there are too many such entities and many of them are rare, so even casting the net across most of Europe would not produce enough cases to enable a robust survival analysis. To address this difficulty, hematologists, pathologists and epidemiologists from several European countries convened under the aegis of a European Cancer Registry-based project on hematologic malignancies (HAEMACARE) to produce a consensus grouping of lymphoid neoplasms (as defined by ICD-O-3 morphology codes and WHO recommendations) into sub-categories based primarily on cell lineage with similar prognosis, of use for clinical and epidemiological studies. The HAEMACARE project made use of data provided by cancer registries participating in EUROCare-4.

The HAEMACARE lymphoid neoplasm grouping system incorporates the changes introduced by the 2001 and 2008 WHO classifications and is consistent with the classification of lymphoid neoplasms for epidemiological research proposed by the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) in 2007, which was recently updated taking into account the revisions of the WHO classification. The InterLymph and HAEMACARE schemes are comparable except that the InterLymph classification regards the obsolete Working Formulation category of malignant lymphoma, mixed small and large cell, diffuse (code 9675) as not otherwise specified (NOS), whereas in the HAEMACARE grouping strategy this category is grouped as diffuse large B-cell lymphoma.

In the present study we estimated 5-year relative survival rates for patients with lymphoid neoplasms diagnosed in Europe in 2000-2002, according to the groups defined by HAEMACARE, and compared survival across European regions according to age and sex.

Design and Methods

Cancer registries

Data on lymphoid neoplasms from 48 cancer registries operating in 20 countries and participating in EUROCare-4 were considered for inclusion in the analysis. The registries were grouped into five regions: Northern Europe (Iceland, Norway and Sweden); UK and Ireland (England, Ireland, Northern Ireland, Scotland, and Wales); Central Europe (Austria, France, Germany, Switzerland and The Netherlands); Southern Europe (Italy, Malta, Slovenia, and Spain); and Eastern Europe (Czech Republic, Poland, and Slovakia). Eleven of the cancer registries are national registries, the others cover variable percentages of their respective national populations. The number of cases contributed by each registry is shown in Table 1, together with indicators of data quality.

The cancer registries provided data on lymphoid neoplasms diagnosed in 1995-2002; for most cases follow-up was only available to 2008. We estimated 5-year relative survival for cases diagnosed in 2000-2002. Since most of these cases did not have 5 years of follow-up, we used the period method to estimate survival: with this method, survival over the years for which follow-up data were unavailable was estimated from the survival experience of patients diagnosed in recent time periods.

To obtain a set of cases with adequately specified morphology, we excluded cancer registries in which NOS morphology constituted over 30% of cases. The ICD-O-3 NOS codes are: lymphoma 9590, NHL 9591, and lymphatic leukemia 9820 and 9832. The cancer registries of Sweden, Northern Ireland, Austria, Friuli Venezia-Giulia (Italy), Reggio Emilia (Italy), Umbria (Italy), and Cracow (Poland) were excluded for this reason. The resulting study population, from the remaining 41 cancer registries, consisted of 138,581 cases.

HAEMACARE categories of lymphoid neoplasms

HAEMACARE grouped lymphoid neoplasm morphological entities (defined by ICD-O-3 codes) into six major categories: Hodgkin’s lymphoma (HL), mature B-cell neoplasms, mature T-cell and natural killer cell neoplasms (T-NK), precursor cell neoplasms, composite Hodgkin’s and non-Hodgkin’s lymphoma, and unknown type lymphoid neoplasm (NOS). Each of these categories was further divided into sub-categories of similar cell lineage and prognosis (Table 2). There were very few cases of composite Hodgkin’s and non-Hodgkin’s lymphoma (29 cases) and B-cell prolymphocytic leukemia (14 cases), for completeness and to comply with WHO indications, we present data for these entities, but do not include them in the survival analyses.

Statistical analysis

Five-year relative survival, by HAEMACARE groups, was estimated overall and for each European region for patients diagnosed in 2000-2002, using the period approach. Survival was also estimated by sex and age. We present relative survival rates in accordance with standard practice for comparative population-based cancer-survival analyses. Relative survival was estimated as the ratio of the observed survival of patients with cancer to the expected survival of a group of people of the corresponding sex and age in the general population. Expected survival was based on cancer registry area-specific or country-specific official mortality data, and was estimated according to Hakulinen’s method. The analyses were carried out using SEER*Stat software.
### Table 1. Lymphoid neoplasms diagnosed in 1995-2002 and recorded in 48 European cancer registries, with data quality indicators

<table>
<thead>
<tr>
<th>Country/Area</th>
<th>N. of cases</th>
<th>Lost to follow-up (%)</th>
<th>DCO/autopsy (%)</th>
<th>Microscopically verified (%)</th>
<th>Poorly specified (NOS) neoplasms (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Northern Europe</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICELAND</td>
<td>501</td>
<td>0.0</td>
<td>0.2</td>
<td>99.6</td>
<td>2.4</td>
</tr>
<tr>
<td>NORWAY</td>
<td>9,752</td>
<td>0.4</td>
<td>1.5</td>
<td>96.5</td>
<td>18.4</td>
</tr>
<tr>
<td>SWEDEN</td>
<td>19,463</td>
<td>0.2</td>
<td>1.8</td>
<td>99.9</td>
<td>40.3</td>
</tr>
<tr>
<td><strong>UK and Ireland</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UK England</td>
<td>66,322</td>
<td>0.0</td>
<td>2.8</td>
<td>87.7</td>
<td>24.3</td>
</tr>
<tr>
<td>IRELAND</td>
<td>7,271</td>
<td>0.0</td>
<td>2.1</td>
<td>95.6</td>
<td>24.2</td>
</tr>
<tr>
<td><strong>Central Europe</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AUSTRIA</td>
<td>13,775</td>
<td>0.0</td>
<td>11.2</td>
<td>86.8</td>
<td>37.6</td>
</tr>
<tr>
<td>France</td>
<td>1,278</td>
<td>0.0</td>
<td>0.0</td>
<td>100.0</td>
<td>3.4</td>
</tr>
<tr>
<td>Germany</td>
<td>2,276</td>
<td>0.0</td>
<td>0.0</td>
<td>100.0</td>
<td>3.4</td>
</tr>
<tr>
<td><strong>Switzerland</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basel</td>
<td>793</td>
<td>1.5</td>
<td>1.9</td>
<td>96.6</td>
<td>11.7</td>
</tr>
<tr>
<td>Geneva</td>
<td>902</td>
<td>4.0</td>
<td>0.4</td>
<td>97.0</td>
<td>17.9</td>
</tr>
<tr>
<td>St. Gallen</td>
<td>1,044</td>
<td>1.1</td>
<td>1.2</td>
<td>98.5</td>
<td>6.6</td>
</tr>
<tr>
<td>Ticino</td>
<td>791</td>
<td>2.5</td>
<td>3.3</td>
<td>94.4</td>
<td>9.1</td>
</tr>
<tr>
<td><strong>The Netherlands</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amsterdam IKN</td>
<td>5,631</td>
<td>0.1</td>
<td>0.5</td>
<td>98.8</td>
<td>4.2</td>
</tr>
<tr>
<td>Eindhoven IKZ</td>
<td>1,524</td>
<td>0.0</td>
<td>0.0</td>
<td>97.5</td>
<td>11.8</td>
</tr>
<tr>
<td>North Netherlands</td>
<td>3,704</td>
<td>0.0</td>
<td>0.0</td>
<td>98.4</td>
<td>7.9</td>
</tr>
<tr>
<td>Twente</td>
<td>2,192</td>
<td>0.6</td>
<td>0.8</td>
<td>98.5</td>
<td>8.1</td>
</tr>
<tr>
<td><strong>Southern Europe</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Italy</td>
<td>41,222</td>
<td>0.8</td>
<td>1.2</td>
<td>93.0</td>
<td>20.2</td>
</tr>
<tr>
<td>Alto Adige</td>
<td>1,107</td>
<td>0.0</td>
<td>0.2</td>
<td>98.5</td>
<td>11.4</td>
</tr>
<tr>
<td>Biella</td>
<td>681</td>
<td>0.2</td>
<td>1.2</td>
<td>93.1</td>
<td>5.6</td>
</tr>
<tr>
<td>Ferrara</td>
<td>1,252</td>
<td>0.8</td>
<td>1.7</td>
<td>97.0</td>
<td>9.3</td>
</tr>
<tr>
<td>Firenze</td>
<td>3,672</td>
<td>0.1</td>
<td>0.7</td>
<td>74.9</td>
<td>22.1</td>
</tr>
<tr>
<td>Friuli V.G.*</td>
<td>4,049</td>
<td>0.9</td>
<td>1.6</td>
<td>99.4</td>
<td>37.1</td>
</tr>
<tr>
<td>Genova</td>
<td>2,449</td>
<td>0.0</td>
<td>0.0</td>
<td>86.2</td>
<td>8.3</td>
</tr>
<tr>
<td>Modena</td>
<td>2,139</td>
<td>1.8</td>
<td>0.3</td>
<td>99.5</td>
<td>5.4</td>
</tr>
<tr>
<td>Napoli</td>
<td>579</td>
<td>5.0</td>
<td>1.0</td>
<td>86.5</td>
<td>22.1</td>
</tr>
<tr>
<td>Parma</td>
<td>1,513</td>
<td>0.6</td>
<td>0.0</td>
<td>99.7</td>
<td>19.7</td>
</tr>
<tr>
<td>Ragusa</td>
<td>598</td>
<td>0.0</td>
<td>1.2</td>
<td>89.5</td>
<td>13.0</td>
</tr>
<tr>
<td>Reggio Emilia*</td>
<td>1,337</td>
<td>0.1</td>
<td>0.1</td>
<td>95.7</td>
<td>57.4</td>
</tr>
<tr>
<td>Romagna</td>
<td>3,594</td>
<td>0.3</td>
<td>2.2</td>
<td>97.5</td>
<td>10.9</td>
</tr>
<tr>
<td>Salerno</td>
<td>1,823</td>
<td>8.0</td>
<td>1.3</td>
<td>95.6</td>
<td>26.0</td>
</tr>
<tr>
<td>Sassari</td>
<td>1,154</td>
<td>0.0</td>
<td>0.2</td>
<td>95.5</td>
<td>5.9</td>
</tr>
<tr>
<td>Torino</td>
<td>2,373</td>
<td>0.1</td>
<td>1.6</td>
<td>94.1</td>
<td>17.3</td>
</tr>
<tr>
<td>Trento</td>
<td>819</td>
<td>0.4</td>
<td>0.5</td>
<td>97.4</td>
<td>13.1</td>
</tr>
<tr>
<td>Umbria*</td>
<td>2,436</td>
<td>0.9</td>
<td>0.7</td>
<td>79.9</td>
<td>42.9</td>
</tr>
<tr>
<td>Veneto</td>
<td>4,652</td>
<td>0.6</td>
<td>1.5</td>
<td>93.1</td>
<td>23.6</td>
</tr>
<tr>
<td>MALTA</td>
<td>701</td>
<td>0.0</td>
<td>0.7</td>
<td>95.6</td>
<td>17.3</td>
</tr>
<tr>
<td>SLOVENIA</td>
<td>3,049</td>
<td>0.1</td>
<td>1.4</td>
<td>99.6</td>
<td>11.8</td>
</tr>
<tr>
<td>Spain</td>
<td>Girona</td>
<td>1,245</td>
<td>0.1</td>
<td>2.3</td>
<td>97.3</td>
</tr>
<tr>
<td><strong>Eastern Europe</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Czech Republic</td>
<td>12,996</td>
<td>0.2</td>
<td>6.8</td>
<td>91.9</td>
<td>20.0</td>
</tr>
<tr>
<td>Poland</td>
<td>980</td>
<td>1.7</td>
<td>4.1</td>
<td>97.8</td>
<td>41.8</td>
</tr>
<tr>
<td>Kielce</td>
<td>1,748</td>
<td>0.0</td>
<td>0.0</td>
<td>85.8</td>
<td>29.1</td>
</tr>
<tr>
<td>Warsaw</td>
<td>2,185</td>
<td>0.1</td>
<td>1.4</td>
<td>92.0</td>
<td>24.3</td>
</tr>
<tr>
<td>SLOVAKIA</td>
<td>6,502</td>
<td>0.0</td>
<td>10.7</td>
<td>92.8</td>
<td>14.5</td>
</tr>
<tr>
<td>EUROCARE pool</td>
<td>184,166</td>
<td>0.3</td>
<td>3.0</td>
<td>92.0</td>
<td>23.5</td>
</tr>
</tbody>
</table>

*Data from cancer registries with more than 30% of NOS cases are not included in the survival analyses. Cancer registries in upper case cover entire national populations.
Table 2. Total number of lymphoid neoplasms diagnosed in 1995-2002 and archived by 41 European cancer registries, together with mean number of cases used to estimate survival, and period estimates for 2000-2002 of 5-year relative survival.

<table>
<thead>
<tr>
<th>HAEMACARE grouping</th>
<th>ICD-O-3 morphology Code</th>
<th>ICD-O-3 description</th>
<th>N. of cases 1995-2002</th>
<th>Mean N. of cases*</th>
<th>Overall 5-year period survival (95%CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hodgkin’s lymphoma, total</strong></td>
<td></td>
<td></td>
<td>12,405</td>
<td>4,730</td>
<td>84.5 (83.2-85.7)</td>
</tr>
<tr>
<td>Hodgkin’s lymphoma, nodular lymphocyte predominant</td>
<td>9659</td>
<td>Hodgkin’s lymphoma, nodular lymphocyte predominant</td>
<td>360</td>
<td>137.5</td>
<td>95.8 (91.4-100.0)</td>
</tr>
<tr>
<td>Classical Hodgkin’s lymphoma</td>
<td></td>
<td></td>
<td>12,045</td>
<td>4,563.5</td>
<td>84.0 (82.8-85.3)</td>
</tr>
<tr>
<td>9650</td>
<td>Hodgkin’s lymphoma, NOS¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9661</td>
<td>Hodgkin’s granuloma [obsolete]</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9662</td>
<td>Hodgkin’s sarcoma [obsolete]</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9651</td>
<td>Hodgkin’s lymphoma, lymphocyte rich</td>
<td></td>
<td>576</td>
<td>204.5</td>
<td>93.1 (88.3-97.8)</td>
</tr>
<tr>
<td>9663</td>
<td>Hodgkin’s lymphoma, nodular sclerosis (NOS)¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9664</td>
<td>Hodgkin’s lymphoma, nodular sclerosis cellular phase</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9665</td>
<td>Hodgkin’s lymphoma, nodular sclerosis, grade 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9667</td>
<td>Hodgkin’s lymphoma, nodular sclerosis grade 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9652</td>
<td>Hodgkin’s lymphoma, mixed cellularity, NOS¹</td>
<td></td>
<td>2,164</td>
<td>813.5</td>
<td>75.0 (40.5-68.3)</td>
</tr>
<tr>
<td>9653</td>
<td>Hodgkin’s lymphoma, lymphocyte depletion, (NOS)¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9654</td>
<td>Hodgkin’s lymphoma, lymphocyte depletion, diffuse fibrosis</td>
<td></td>
<td>7,054</td>
<td>2,710.0</td>
<td>87.8 (86.3-89.2)</td>
</tr>
<tr>
<td>9655</td>
<td>Hodgkin’s lymphoma, lymphocyte depletion, reticular</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mature B-cell neoplasms</strong></td>
<td></td>
<td></td>
<td>63,556</td>
<td>33,907</td>
<td>53.9 (53.2-54.5)</td>
</tr>
<tr>
<td>Chronic lymphocytic leukemia/small lymphocytic lymphoma</td>
<td>9670</td>
<td>Malignant lymphoma, small B-cell lymphocytic, NOS¹ B-cell chronic lymphocytic leukemia</td>
<td>22,871</td>
<td>8487.5</td>
<td>69.1 (67.7-70.5)</td>
</tr>
<tr>
<td>9823</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immunoproliferative diseases</td>
<td>9671</td>
<td>Malignant lymphoma, lymphoplasmacytic Immunoproliferative disease, NOS¹ Waldenström’s macroglobulinemia</td>
<td>4,128</td>
<td>1531.5</td>
<td>66.2 (63.0-69.4)</td>
</tr>
<tr>
<td>9760</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9761</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9762</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mantle cell lymphoma</td>
<td>9673</td>
<td>Mantle cell lymphoma</td>
<td>2,055</td>
<td>789.0</td>
<td>43.8 (39.7-47.8)</td>
</tr>
<tr>
<td>Follicular lymphoma</td>
<td>9690</td>
<td>Follicular lymphoma, NOS¹</td>
<td>9,392</td>
<td>3635.5</td>
<td>72.8 (71.0-74.6)</td>
</tr>
<tr>
<td>9691</td>
<td>Follicular lymphoma, grade 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9695</td>
<td>Follicular lymphoma, grade 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9698</td>
<td>Follicular lymphoma, grade 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diffuse large B-cell lymphoma</td>
<td>9675</td>
<td>Malignant lymphoma, mixed small and large cell, diffuse [obsolete] Primary effusion lymphoma</td>
<td>18,685</td>
<td>7164.5</td>
<td>49.3 (47.8-50.6)</td>
</tr>
<tr>
<td>9678</td>
<td>Medialinal large B-cell lymphoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9679</td>
<td>Malignant lymphoma, large B-cell, diffuse, NOS¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9680</td>
<td>Malignant lymphoma, B large cell, diffuse, immunoblastic, NOS¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Burkitt’s lymphoma</td>
<td>9687</td>
<td>Burkitt’s lymphoma, NOS¹ Burkitt cell leukemia</td>
<td>949</td>
<td>368.5</td>
<td>56.0 (50.7-61.2)</td>
</tr>
<tr>
<td>9826</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marginal zone lymphoma</td>
<td>9689</td>
<td>Splenic marginal zone B-cell lymphoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9699</td>
<td>Marginal zone B-cell lymphoma, NOS¹ (MALT lymphoma)¹</td>
<td></td>
<td>1,995</td>
<td>797.5</td>
<td>81.4 (77.7-85.2)</td>
</tr>
<tr>
<td>9764</td>
<td>Immunoproliferative small intestinal disease (Mediterranean lymphoma)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B-cell prolymphocytic leukemia</td>
<td>9833</td>
<td>Prolymphocytic leukemia, B-cell type</td>
<td>14</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hairy cell leukemia</td>
<td>9940</td>
<td>Hairy cell leukemia</td>
<td>1,403</td>
<td>527.5</td>
<td>93.9 (90.1-97.7)</td>
</tr>
<tr>
<td>Plasma cell neoplasms</td>
<td>9732</td>
<td>Multiple myeloma</td>
<td>28,064</td>
<td>10299.5</td>
<td>32.6 (31.5-33.7)</td>
</tr>
<tr>
<td>9733</td>
<td>Plasma cell leukemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9731, 9734</td>
<td>Plasma cytoma NOS¹, plasmacytoma, extramedullary</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mature T-cell and NK-cell neoplasms</strong></td>
<td></td>
<td></td>
<td>5,149</td>
<td>2,051</td>
<td>60.1 (57.6-62.7)</td>
</tr>
<tr>
<td>T lymphoma cutaneous</td>
<td>9700</td>
<td>Mycosis fungoides</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9701</td>
<td>Sézary’s syndrome</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9709</td>
<td>Cutaneous T-cell lymphoma, NOS¹</td>
<td></td>
<td>2,620</td>
<td>1,046.5</td>
<td>83.4 (80.0-86.7)</td>
</tr>
<tr>
<td>9718</td>
<td>Primary cutaneous CD30⁺ T-cell-lymphoproliferative disorder</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9708</td>
<td>Subcutaneous T panniculitis-like T-cell lymphoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*continued on the next page*
Results

Table 1 shows the total number of cases, divided by registry and by European region, with quality indicators. The quality indicators are percentages of cases lost to follow-up, cases determined by death certificate only or notified autopsy (DCO/autopsy), cases microscopically confirmed, and cases with NOS morphology.

Overall, 0.3% of cases were lost to follow-up, with the highest figures in Southern Europe (0.8%; range, 0.0-8.0%). Overall 3.0% of cases were DCO/autopsy, with highest proportions in Central Europe (5.5%; range, 0.0-11.2%) and Eastern Europe (6.8%; range, 0.0-10.7%). Overall, 92.0% of cases were microscopically verified, although the percentages were lower for UK and Ireland (37.7%) and particularly low for Wales (35.6%), where a large proportion of pathology records was not available to the registry. The proportion of NOS cases was similar across regions (19.5 to 24.3%), but was particularly high in Northern Europe (32.5%; range, 2.4-40.3%). Considering individual cancer registries, the proportion of NOS cases varied more than the other quality indicators, ranging from 2.4% (Iceland) to 57.4% (Reggio Emilia).

Survival of patients according to HAEMACARE group and sex

Table 2 shows, for each ICD-O-3 entity and HAEMACARE group, the total numbers of cases of lymphoid neoplasms diagnosed in 1995-2002, the number of cases contributing to the period estimates of 5-year relative survival for 2000-2002, and the period estimate of 5-year relative survival with corresponding 95% confidence intervals for 2000-2002.

The 5-year relative survival rate was 57% overall but varied markedly according to HAEMACARE group. Relative survival was highest for patients with nodular lymphocyte predominant Hodgkin’s lymphoma (95.8%), hairy cell leukemia (93.9%), classical Hodgkin’s lymphoma (84.0%) and T cutaneous lymphoma (83.4%). This last group consisted mainly of patients with mycosis fungoides. Survival was lowest for patients with mantle cell lymphoma (48.8%), other T/NK-cell lymphomas (38.6%), and plasma cell neoplasms (32.6%).

Figure 1 shows 5-year relative survival by sex and HAEMACARE group. Overall survival was similar in males (57.0%) and females (56.7%). Survival was also similar between the sexes within the individual HAEMACARE groups, although better survival in females than males was found for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Survival of patients in HAEMACARE groups according to age at diagnosis

Online Supplementary Table S4 shows the distribution of patients in HAEMACARE groups by age category and European region. Approximately 80% of all lymphoid neoplasms occurred in patients over 50 years, and only 3.4% occurred in patients under 14 years. The proportions of the different subtypes of lymphoid neoplasms also varied markedly with age. Thus 5.2% of HL, 24.2% of Burkitt’s lymphoma/leukemia (BL) and 52.5% of precursor cell neoplasms occurred in patients under 14 years, whereas 63.8% of HL, 39.1% of BL and 25.7% of precursor cell neoplasms occurred in the age group from 15-49 years old. Follicular lymphoma (FL) (48.5%), hairy cell leukemia (HCL) (46.1%) and mantle cell lymphoma (MCL) (45.6%) were mainly diagnosed in the age group from 50-69 years old. Over half of the patients with CLL/SLL, immunoproliferative diseases, plasma cell neoplasms, and B-cell prolymphocytic leukemia were 70 years or older. The proportion of NOS increased substantially with age, from 1.4% in children under 14 to 47.9% in adults over 80.

<table>
<thead>
<tr>
<th><strong>Other T and NK-cell lymphomas</strong></th>
<th><strong>Mature T-cell lymphoma, NOS</strong></th>
<th><strong>Angioimmunoblastic T cell lymphoma</strong></th>
<th><strong>Anaplastic large cell lymphoma, T-cell and null cell type</strong></th>
<th><strong>Hepatosplenic gamma delta cell lymphoma</strong></th>
<th><strong>Intestinal T-cell lymphoma</strong></th>
<th><strong>Aggressive NK-cell leukemia</strong></th>
<th><strong>NK/T cell lymphoma, nasal and nasal type</strong></th>
<th><strong>Adult T-cell leukemia/lymphoma (HTLV-I positive)</strong></th>
<th><strong>T-cell large granular lymphocytic leukemia</strong></th>
<th><strong>Prolymphocytic leukemia, T-cell type</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>9702</td>
<td>9705</td>
<td>9714</td>
<td>9716</td>
<td>9717</td>
<td>9948</td>
<td>9719</td>
<td>9827</td>
<td>9831</td>
<td>9834</td>
<td></td>
</tr>
<tr>
<td>2,529</td>
<td>987.5</td>
<td>38.6 (35.2-41.9)</td>
<td>51.8</td>
<td>56.9 (53.5-59.5)</td>
<td>248</td>
<td>51.8</td>
<td>56.9 (53.5-59.5)</td>
<td>56.9 (53.5-59.5)</td>
<td>56.9 (53.5-59.5)</td>
<td></td>
</tr>
</tbody>
</table>

1NOS: not otherwise specified; 2Mean number of cases contributing to period survival estimates for 2000-2002; 3M marrow zone B-cell lymphoma, NOS (ICD-O-3 code 9699) includes both MALT lymphoma and nodal marginal zone lymphoma, if site is not known.
in people over 70 years old.

Online Supplementary Figure S1 shows trends in 5-year relative survival rates for 2000-2002 according to age at diagnosis. In general survival decreased with advancing age at diagnosis and fell particularly markedly after the age of 50. The survival rate for patients with precursor cell neoplasms fell dramatically from 84.4% in patients under 14 years old, to 8.8% in patients over 70 years old. A similarly marked decline with age was also found for classical HL, BL, and NHL.

Patients with diffuse large B-cell lymphoma (DLBCL) and other T/NK-cell lymphomas had the worst survival (74.4% and 72.0%, respectively) in the youngest age category, although for both these entities the number of cases was low, complicating interpretation.

The survival rate of patients with plasma cell neoplasms, mainly represented by multiple myeloma, was significantly higher among patients under 50 years old (59.0%) than among older patients (50-69 years, 39.6%; 70-99 years, 21.9%).

**Distribution of HAEMACARE groups by region**

HL and precursor cell neoplasms formed high proportions of cases in Eastern Europe (Table 2) (15.2% and 61.1%), while mature B-cell and T/NK-cell neoplasms formed high proportions of all cases in Central Europe (74.6% and 4.7%) and Southern Europe (67.9% and 4.8%) (Online Supplementary Table S1). DLBCL formed the highest proportion of cases in Central Europe (20.3%), and the lowest in Eastern Europe (9.6%). Marginal zone lymphomas were uncommon in Eastern Europe (0.5%) and the UK and Ireland (0.5%). MCL accounted for 1.5% of all lymphoid neoplasms in Europe (range, from 1.2% in UK and Ireland to 1.3% in Southern and Central Europe).

Figure 2 shows 5-year relative survival rates divided by HAEMACARE group and region. For most HAEMACARE entities, survival was similar across regions, although for CLL/SLL and immunoproliferative diseases, survival was significantly lower in Eastern Europe than in other regions.

**Discussion**

This study provides a comparative analysis of 5-year relative survival rates for patients diagnosed with lymphoid neoplasms in 2000-2002, according to HAEMACARE group, age, and sex, across European regions. To our knowledge this is the first population-based study on a large European dataset. It is also novel because it groups individual lymphoid neoplasm entities (defined by ICD-O-3 code) into HAEMACARE categories based primarily on cell lineage and similar prognosis, and is, therefore, useful for clinical and epidemiological studies. Past population-based studies divided lymphoid neoplasms into broad categories (typically NHL versus HL) to investigate incidence and survival. This is unsatisfactory because survival and incidence vary greatly between ICD-O-3 entities, complicating comparisons and in particular making it difficult to interpret regional differences in survival.

A striking finding of the present study is that survival differences between men and women were small. The exception was CLL/SLL, for which the survival of affected women was better than that of men. Previous studies had found that, among patients with lymphoid neoplasms, the survival of males was worse than that of females.

With regard to the effect of age on survival, we found that survival decreased with advancing age at diagnosis for most HAEMACARE groups, as has been well documented for most types of cancer. The marked lower survival in the oldest patients (Online Supplementary Figure S1) together with the sharp increase in NOS cases with advancing age (Online Supplementary Table S1) point to a decline in the quality of diagnostic workup and of care as the age of the patient increases, suggesting that older patients may not be receiving optimal treatment for their conditions. However, ‘less insistent’ application of potentially effective therapies in the elderly could be due to poor toleration of cytotoxic agents or the frequent presence of comorbidities. In addition, elderly patients are under-represented in randomized clinical trials, so evidence-based treatment guidelines specifically for the elderly are lacking.

For most lymphoid neoplasms, survival did not vary significantly across the five European regions. This finding suggests a major increase in survival of patients with these diseases in Eastern European countries compared to earlier years. The exceptions were for CLL/SLL and immunoproliferative diseases, with survival in Eastern Europe being significantly lower than in other European regions. Incomplete registration of CLL/SLL cases with better sur-
vival may account for the difference: CLL/SLL cases with a better prognosis are generally diagnosed on an outpatient basis, so reporting sources are usually pathology laboratories and doctors’ offices. These cases are more likely to be unreported than the poorer prognosis cases treated in (and reported by) hospitals. This could be particularly true for Eastern European countries, where the relatively low total national expenditure on health compared to that of other regions may have lowered hospital admissions for patients potentially treatable at home.

We might have expected to see more marked survival differences between regions for DLBCL and FL in relation to a heterogeneous introduction of the use of rituximab. Rituximab is a monoclonal antibody that binds the B-cell transmembrane protein CD20 resulting in lymphoma cell lysis. It started to be used in Europe in 2000, but not simultaneously in all countries and significant survival improvements for DLBCL and FL patients treated with rituximab have been described in a population-based study.

The treatment of multiple myeloma has also changed over the last decade with the introduction of thalidomide, lenalidomide and proteasome inhibitors (bortezomib), as add-on therapy to conventional cytotoxic and transplantation regimens. We found that the survival of patients with multiple myeloma was poor at 32.4% and unchanged compared to the 35% reported for 1995-1999 by EURO-CARE-4. A US study reported a similar survival rate (30%) for the same time period. By contrast, survival of patients with multiple myeloma was significantly better (59%) in European patients under 50 years old, as also observed in the USA. The US study found a significant increase in survival for younger patients from 1990-1992 to 2002-2004, but only a moderate improvement for older patients. Improvements in survival of patients with DLBCL, FL and multiple myeloma may become evident after 2004, in relation to more extensive application of the new treatments. Only longitudinal data from population-based studies can show whether these treatments lead to real survival improvements.

The strengths of our study are its large size (~140,000 cases), European scope, and use of the period method to estimate 5-year relative survival rates when follow-up was shorter than 5 years. An important limitation regards data quality. Overall, around 16% of the cases we analyzed were NOS and this figure varied considerably with European region (Online Supplementary Table S1). Non-specification of the morphology of lymphoid neoplasms results in misclas-
sification of subtype-specific distribution, and biases the survival analyses since the majority of NOS cases have poor prognoses. Erroneous automatic conversion of ICD-O codes from previous to recent versions could be responsible for some of the NOS cases. In addition, the low proportions, in some regions, of entities first recognized in the 2001 WHO classification (e.g. marginal zone lymphomas) suggests that many of these entities were simply classified as NOS. A central pathology review would have reduced the number of NOS cases but this is not feasible in population-based studies involving tens or hundreds of thousands of cases. Nevertheless, the relatively high percentage of NOS cases pinpoints the need to improve the quality of data on hematologic malignancies archived by cancer registries. It is noteworthy that the overall percentage of NOS cases declined from 26% in 1995 to 19.8% in 2002 (data not presented) so there was an encouraging improvement over the study period. It is also worth noting that we had a very few cases of composite HL/NHL (n=29). We suspect that this may be an artificially low number, perhaps because of the complexities of the procedures employed by cancer registries for coding multiple malignancies. Furthermore, composite HL/NHL cases are not recorded by European cancer registries; the coexistence of multiple NHL with the same immunophenotype (particularly the not uncommon occurrence of FL with DLBLCL) is not accounted for by cancer registries. This is certainly related to the fact that there is no code in the ICD-O-3 for such cases to be registered.

In conclusion, our findings show that survival for most subtypes of lymphoid neoplasms declined sharply – while the proportion of NOS cases increased steeply – with age at diagnosis, suggesting under-treatment in the elderly, while survival differences between the sexes were small. The comparison of our overall data with those of previous analyses suggests a decline in survival differences across European regions. We emphasize, however, that useful comparisons of survival of patients with lymphoid neoplasms across regions (and over time) require that the individual neoplastic entities be grouped into clinically meaningful categories with similar prognoses; the HAEMACARE groupings used in the present study appear eminently suitable for this purpose. The final message of this paper is that although the quality of cancer registry data on lymphoid neoplasms needs to be improved and the data integrated with detailed information (immunophenotype, genetic abnormalities, molecular data and clinical data) necessary for classifying these diseases according to the latest WHO classification, the information presently available in cancer registries represents a good benchmark for further descriptive and analytical studies.

HAEMACARE Working Group

Austria: Hackl M (National Cancer Registry of Austria); Czech Republic: Holub J (West Bohemia Cancer Registry); France: Maynadie M (Côte d’Or Haematological Malignancies Cancer Registry); Germany: Holleczek B (Saarland Cancer Registry); Iceland: Tryggvadottir I (National Cancer Registry of Iceland); Ireland: Comber H (National Cancer Registry of Ireland); Italy: Bella F (Alto Adige Cancer Registry), Giacomin A (Biella Cancer Registry), Ferretti S (Ferrara Cancer Registry), Crocetti E (Firenze Cancer Registry), Serraino D (Friuli Cancer Registry), Vercelli M (Liguria Cancer Registry, IST/Università di Genova, Genoa), Federico M (Modena Cancer Registry), Fusco M (Napoli Cancer Registry), Miachira M (Parma Cancer Registry), Tumino R (Ragusa Cancer Registry), Mangone L (Reggio Emilia Cancer Registry), Falcini F (Romagna Cancer Registry), Iannelli A (Salerno Cancer Registry), Buondoni M (Sassari Cancer Registry), Zanetti R (Torino Cancer Registry), Piffer S (Trento Cancer Registry), La Rosa F (Umbria Cancer Registry), Zamponi P (Venetian Cancer Registry), Sant M (Project Leader), Allemani C, Berrino F, Sowe S, Terezani C (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan), Capocaccia R, De Angelis R, Simonetti A (National Centre for Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanità, Rome); Malta: Engel K (National Cancer Registry of Malta); Norway: Langmark F (National Cancer Registry of Norway); Poland: Rachtaj J (Cracow Cancer Registry), Mezyk R (Rzeszow Cancer Registry), Zwiekos M (Warsaw Cancer Registry); Slovakia: Ondrussova M (National Cancer Registry of the Slovak Republic); Slovenia: Prinic-Žakelj M (National Cancer Registry of Slovenia); Spain: Marcos-Gregora R (Girona Cancer Registry); Sweden: Khan S (National Cancer Registry of Sweden); Switzerland: Jundt G (Basel Cancer Registry), Uesl M (Geneva Cancer Registry), Ess SM (St. Gall Cancer Registry), Bordoni A (Tino Cancer Registry), The Netherlands: Visser O (Amsterdam Cancer Registry), Otter O (CCC-Groningen, North Netherlands), Coebergh JW (Eindhoven Cancer Registry), Stiesling S (CCC-Stedelijkziekenhuis Twente); UK-England: Greenberg D (Eastern Cancer Registration and Information Centre), Easley N (Northern and Yorkshire Cancer Registry), Roche M (Oxford Cancer Intelligence Unit), Lawrence G (West-Midlands Cancer Intelligence Unit); UK-Northern Ireland: Gavin A (Northern Ireland Cancer Registry); UK-Scotland: Brewster DH (Scottish Cancer Registry); UK-Wales: Steward J (Welsh Cancer Intelligence & Surveillance Unit).

Authorship and Disclosures

The information provided by the authors about contributions from persons listed as authors and in acknowledgments is available with the full text of this paper at www.haematologica.org.

Financial and other disclosures provided by the authors using the ICMJE (www.icmje.org) Uniform Format for Disclosure of Competing Interests are also available at www.haematologica.org.

References


